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Systemic Th17 response in the 
presence of periodontal inflammation
The relationship between periodontitis and the pathogenesis of other 
inflammatory diseases, such as diabetes, rheumatoid arthritis and obesity 
has been an important topic of study in recent decades. The Th17 pathway 
plays a significant role in how local inflammation can influence systemic 
inflammation in the absence of systemic pathology. Objective: To determine 
Th17 biased-cells in systemically healthy patients in the presence of 
generalized chronic periodontitis. Methodology: A total of 28 patients were 
recruited without systemic inflammatory pathology, which was determined by 
clinical history, the Health Assessment Questionnaire (HAQ) and rheumatoid 
factor detection. Of these patients, 13 were diagnosed as healthy/gingivitis 
(H/G) and 15 as generalized chronic periodontitis (GCP). Th17 (CD4+CD161+) 
cells and Th17IL23R+ (CD4+CD161+IL-23R+) cells were quantified by flow 
cytometry, based on the total cells and on the lymphocyte region, termed 
the “enriched population” (50,000 events for each). Results: The percentages 
of Th17 cells of the H/G and periodontitis groups were similar on total cells 
and enriched population (19 vs 21.8; p=4.134 and 19.6 vs 21.8; p=0.55). 
However, Th17IL23R+ cells differ significantly between periodontally healthy 
patients and generalized chronic periodontitis patients in both total cell 
(0.22% vs 0.65%; p=0.0004) and enriched populations (0.2% vs 0.75%; 
p=0.0266). Conclusions: GCP patients (otherwise systemically healthy) were 
characterized by increased Th17-proinflammatory cell phenotype positive 
for the IL-23 receptor in peripheral blood. The proportion of Th17 cells that 
are negative for the IL-23 receptor in the peripheral blood of systemically 
healthy patients seemed to be unaffected by the presence or absence of 
chronic periodontitis.
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Introduction
Periodontitis, currently recognized as a chronic 
inflammatory disease, has been linked to many other 
proinflammatory pathologies. During inflammation 
pathogenesis, naïve T helper (Th) cells are activated 
by recognition of a peptide antigen–class II major 
histocompatibility complex presented by antigen-
presenting cells and their interaction with the T-cell 
receptor. After activation, Th cells divide and give rise 
to different clones of CD4+ effector cells, which can 
be divided into three main types; Th type-1 (Th1), 
Th type-2 (Th2) and Th type-17 (Th17) cells.1 Each 
type of effector cell phenotype presents different 
profiles of cytokine secretion eliciting unique functional 
characteristics during the inflammatory response.
Th17 cells differentiate into subprofiles with 
functions determined by the cytokines in the 
environment and characterized by the expression 
of surface markers. CD161, also known as killer 
cell lectin-like receptor B1 (KLRB1), is a marker 
associated with the pathogenesis of inflammatory 
diseases2 by T-cell proliferation and induction of Th1 
cytokine secretion. CD161 is a marker of all human 
T-cells producing IL-17. Th17 cells originate from 
the subpopulation of CD4+CD161+ cells that express 
RORC2 and IL-23R.3,4 The naïve CD4+ initially 
differentiates into Th17 in the presence of TGF-b 
and IL-6. However, subsequent exposure to IL-23 is 
required for functional maturation, the maintenance 
of their phenotype and the acquisition of pathogenic 
functions. IL-23 regulates the overexpression of IL-
23R directly or indirectly through TGF-b3 to increase 
its own signal and induce functionally mature Th17 
pathogenic cells. In the absence of IL-23 signal, Th17 
cells differentiate into non-pathogenic Th17-producing 
IL-10.5 
Th17 cells play a central role in many inflammatory 
diseases, such as rheumatoid arthritis, ankylosing 
spondylitis, stomach cancer, chronic obstructive 
pulmonary disease,6-12 and periodontitis. Recently, it 
has been demonstrated in an animal model that the 
expansion of Th17 cells13 and the conversion of Foxp3+ 
T cells to exFoxp3Th17 cells14 are associated with the 
periodontitis pathogenesis. A significantly greater 
increase in IL-23 receptor expression was found in 
tissues with periodontitis compared with healthy 
tissues, thus confirming the importance of Th17/IL-23 
axis activation in periodontal inflammation.15
The evidence of low magnitude inflammation in 
a systemic level caused by local infections in the 
periodontium is the key link between periodontitis 
and other systemic inflammatory diseases. Th17 
subpopulations could be mediating this important 
effect.16,17 Th17 cell populations in the blood could 
potentially procure or perpetuate inflammation in 
patients with periodontal disease and could also 
eventually constitute a biological marker, which 
explains disease progression or activity.16,18 The 
study of Th17 populations may also explain how 
local infections in the periodontium influence the 
progression and prognosis of other related systemic 
diseases. Therefore, this study aimed to compare the 
percentages of Th17 (non-pathogenic) and Th17IL-
23R+ (pathogenic) cells in systemically healthy patients 
in the presence of generalized chronic periodontitis.
Methodology
Patient selection
After institutional review board (IRB) approval 
(Universidad Nacional CIE-107-13), a sample of 
patients attending Universidad Nacional Dental School, 
who met the following inclusion criteria, was selected: 
18+ years of age, systemically healthy, and having at 
least 20 teeth. The clinical periodontal examination 
was performed by probing six surfaces around 
the teeth to determine pocket depth, bleeding on 
probing and clinical attachment level. The periodontal 
diagnosis was confirmed per the criteria of the 
American Academy of Periodontology19 and further 
classified as healthy/plaque-induced gingivitis (H/G) 
or generalized chronic (mild, moderate or severe) 
periodontitis (GCP).20 Patients were excluded if they 
were pregnant or lactating, had systemic diseases 
(controlled or uncontrolled), received antibiotics, 
anti-inflammatory or corticosteroid therapy within 6 
months prior to consultation (or required antibiotic 
prophylaxis prior to dental treatment) or were 
rheumatoid factor-positive. All recruited patients 
were surveyed to determine clinical manifestations 
of rheumatoid arthritis per the Health Assessment 
Questionnaire (HAQ).21,22 The rheumatoid factor was 
detected by the latex method (HumaTex RF, LabMark, 
Praha, Czech Republic). Absence of agglutination was 
considered negative (RF<12 IU/mL).
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Peripheral blood collection, antibody staining 
and flow cytometry analysis
After obtaining patient informed consent, 50 
mL peripheral blood was obtained by venipuncture 
(Beckton-Dickinson, Franklin Lakes, NJ, USA). Blood 
with ethylenediaminetetraacetic acid (EDTA) (Beckton-
Dickinson, Franklin Lakes, NJ, USA) was used to 
quantify Th17 (CD3+CD4+CD161+) and Th17IL-23R+ 
(CD3+CD4+CD161+IL23R+) cells with anti-human 
monoclonal antibodies coupled with the following 
fluorochromes: anti-CD3 PerCP (T cells), anti-CD4 
FITC (Th cells), anti-CD161 APC (marker of all human 
IL-17 producing T cells)2 (BD Biosciences, Pharmingen, 
San Diego, CA, USA) and anti-IL-23R PE (selective 
expression of IL-23 receptor for all human IL-17 
producing T cells)2 (R&D Systems, Minneapolis, MN, 
USA). CANTO II Flow Cytometer (Beckton-Dickinson, 
San José, CA, USA) was used to analyze the cells. 
Data were analyzed using Flowjo 8.7 (FlowJo LLC, 
Ashland, OR, USA). Cell acquisitions were performed 
based on the total cells (50,000 events for all) and 
on the lymphocyte region, which we termed the 
“enriched population of lymphocytes” (50,000 events 
for each region) (Figure 1). For each acquisition, all 
events and enriched populations of lymphocytes were 
analyzed and the value per group was obtained in 
percentages (%) of Th17 and Th17IL-23R+ cells. The 
averages of these populations per patient group were 
then determined. The mean fluorescence intensity for 
the CD161 and IL-23R marker expressions were also 
analyzed.
Statistical analysis
Non-parametric data distribution was observed 
(Shapiro-Wilk p<0.05). Data was reported as a median 
value [interquartile range]. Groups were statistically 
compared by Mann Whitney U test (p<0.05) using 
GraphPad Prism 8 software (San Diego, CA, USA).
Results
A total of 28 patients (9 women and 19 men) 
ranging between 19 and 73 years of age with an 
average age of 34 were recruited. Patients had no 
relatable autoimmune disease. All patients answered 
the HAQ questionnaire to rule out symptoms associated 
with rheumatoid arthritis. Of these, 13 patients (6 
women and 7 men) were included in the H/G group 
and 15 (3 women and 12 men) were included in the 
GCP group. The average age was significantly lower in 
the H/G group compared with the GCP group (Table 1).
Figure 1- Analysis of cell populations by flow cytometry. A dot plot of a representative sample is shown. A: Analysis of total cells (acquisition 
of 50,000 events of all population), R1: Lymphocytes region. R2: CD3+CD4+ cells. R3: CD161+IL-23R+ cells; B: Analysis of enriched 
populations of lymphocytes. R4: Enriched lymphocytes region (acquisition of 50,000 events of this population), the information on the 
CD4+CD161+IL-23R+ cells was obtained in the same way as was done for the total cells
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Analysis of the Th17 cell population of the total 
cells showed no difference in the percentages between 
the H/G and GCP groups (19±5.1% vs 21.8±6.8%, 
p=0.4336). Similarly, no differences were found in 
the enriched lymphocyte population percentages 
(19.6±5.7% vs 21.8±6.705%, p=0.55). However, 
significant differences were found when comparing 
Th17IL-23R+ cells between the groups with respect 
to total cell population (H/G: 0.22±0.21%; GCP: 
0.65±0.52%, p=0.0004) and enriched lymphocyte 
population (H/G: 0.2±0.2%; GCP: 0.75±0.56%, 
p=0.0003) (Figure 2).
Results of mean fluorescence intensity (MFI) for 
CD161 from the CD4+CD161+ phenotype of the total 
cells were 24.1 and 22.8 for the H/G and GCP groups. 
The results for the enriched lymphocyte population 
were 23.8 and 22.7 for the H/G and GCP groups. The 
MFI for IL-23R from the Th17IL-23R+ phenotype of 
the total cells was 8.9 for the H/G group and 9.5 for 
the GCP group. In the enriched population, the values 
were 8.5 and 8.7. These results showed no statistically 
significant differences.
Discussion
The Th17 subpopulation’s key role in the 
pathogenesis of systemic inflammatory diseases 
has been extensively demonstrated. In rheumatoid 
arthritis, the number of Th17 cells increases with 
disease progression. Its presence is crucial in 
regulating cartilage and bone destruction due in part 
to the production of RANKL.23,24 In pathogenesis of 
multiple sclerosis, the proportion of Th1/Th17 cells 
determines the extent of inflammation in the brain 
and spinal cord.25 Th17 cells have been associated with 
the appearance and development of autoimmunity, 
infectious diseases and cancer.26 Nevertheless, not all 
Th17 cells are pathologic. Some populations of Th17 
cells comprise regulatory subtypes and Th1-like cells 
and can be related to controlling disease dissemination 
and inflammation in systemic diseases and local 
infections of the periodontium. Determining the role 
of non-pathologic Th17 subpopulations is critical for 
establishing the prognosis of systemic inflammatory 
diseases in the presence of periodontitis.
Evidence shows that the proportion of Th17 cells 
may reflect the degree of systemic inflammation. 
This could make Th17 cells potential biomarkers of 
disease activity in patients with arthritis and the 
number of cells could help distinguish active disease 
stages27. However, in our study, the percentage of 
Th17 cells was not different between systemically 
healthy patients with and without active GCP. 
Nonetheless, GCP patients had a positive increase in 
cell populations for the IL-23 receptor in this study. 
This receptor is expressed in memory CD4+ and 
CD8+ cells as well as NKT cells.4 With respect to the 
Th17IL-23R+ subpopulation, not all Th17 cells respond 
to IL-23, but the proinflammatory role of Th17CD4+ 
Figure 2- Comparative analysis of the percentage of CD4+CD161+IL-23R+ T lymphocytes between healthy/gingivitis patients (H/G) and 
diagnosed with generalized chronic periodontitis (GCP) on total cells (A) and enriched population of lymphocytes (B). Comparative 
analysis was performed using the Mann-Whitney U test. *p<0.05
Parameters H/G group GCP group
Age 25.8±5.9 43.7±13.4
Probing depth 2.06±0.36 mm 3.13±0.86 mm
Clinical attachment level 0.59±0.32 3.66±1.37
Bleeding on probing 39.1% 77.7%
Table 1- Age average and clinical scores of study groups
H/G group: healthy/plaque-induced gingivitis
GCP group: generalized chronic periodontitis
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cells that do respond to IL-23 is well established in 
many inflammatory disorders.28 IL-23 plays a key 
role as a mediator of endo-organic inflammation 
affecting the intestines, joints and central nervous 
system. Signaling via IL-23R promotes the generation 
of pathological Th17 as well as its contribution to 
several cellular functions including cytokine expansion, 
stabilization and secretion.29 Despite this, the role 
of IL-23 in Th17 functioning remains unclear and its 
role in differentiating this population is controversial. 
However, evidence suggests that IL-23 conditions the 
appearance of a proinflammatory phenotype.28
The results presented here indicate that, of the total 
Th17 cells, few can differentiate into a pathological 
profile (Th17IL-23R+). Low values of cells with this 
phenotype have been reported in the literature and 
vary between 0.42% and 2.69%.6-9 Proportions greater 
than these are considered as a result of chronic 
systemic inflammation, a product of an autoimmune 
process or tumor development.11,12 However, the 
significant increase in this pathological subpopulation 
in the presence of periodontitis may corroborate the 
impact of local infection on the systemic immune 
response mediated by this studied subpopulation. This 
study, to the best of our knowledge, is the first effort 
to further characterize the Th17 systemic response 
in periodontal infections (in otherwise systemically 
healthy individuals). These results should be further 
investigated by studying the different Th17 subprofiles 
by surface phenotyping and cytokine production.
It is also important to demonstrate the inter-
individual differences in the expression levels of IL-23R 
and CD161 as these affect the response to IL-23 and 
therefore contribute to individual susceptibility during 
inflammatory processes. In chronic inflammatory 
diseases, and more specifically in autoimmunity, 
the CD161 fraction of memory T-cells is enriched 
with high IL-23R expression and is required for its 
inflammatory function.30 However, as not all Th17 cells 
are proinflammatory, an approximation of the Th17 
pro or non-inflammatory phenotype was performed 
by analyzing the IL-23 and CD161 expression levels 
measured by the MFI. No statistically significant 
differences were found between the markers or the 
study groups. Although the MFI of IL-23R did not 
differ, these results suggest an increased proportion 
of Th17 cells with “pathological potential” in the 
peripheral blood of systemically healthy patients with 
chronic periodontitis, as well as in other inflammatory 
pathologies. Considering that no ongoing systemic 
inflammatory processes or autoimmune pathology 
were found in the patients included in this study by 
both clinical history and survey (Health Assessment 
Questionnaire, HAQ21,22) and by an absence of the 
rheumatoid factor,6,8 the increased Th17 cell counts 
are hypothesized to have originated in the inflamed 
periodontal tissue. This increase in the IL-23R+ 
population is extremely relevant because this receptor 
expression is related to stabilizing and maintaining 
the Th17 profile.31
One of the study limitations is the age difference 
between the periodontally healthy and periodontitis 
groups. Age can be a determining factor in the systemic 
immune response mediated by Th17 cells. Lee, et al.32 
(2011) found a decreased frequency of Th17 memory 
cells and an increase in the differentiation of effector 
TH17 cells from naïve TCD4 cells in healthy adults 
over 65 years of age compared with young adults 
under 40 years of age. However, in this study, we 
found a differential increase in circulating Th17 cells 
that express the IL-23 receptor in systemically healthy 
individuals with significantly greater periodontal 
disease compared with the H/G group. There are no 
reports showing any relationship in the number of 
CD4IL-23R+ cells with age. Nonetheless, Shen, et al.33 
(2013) report that the CD8CD161+ cells that express 
the IL-23 receptor decrease with age. Therefore, the 
increase in Th17IL-23R+ cells present in peripheral 
blood in subjects with periodontitis in this study may 
be associated with local infection rather than age.
Given the inflammatory nature of periodontitis and 
the evidence demonstrating that chronic periodontal 
infections can activate low-magnitude systemic 
inflammation, the mechanisms by which the immune 
system potentiates inflammatory processes and their 
regulatory mechanisms must be explored.
Conclusion
Local infections may contribute to the pathogenesis 
of other diseases, the increased percentage of Th17IL-
23R+ cells in systemically healthy patients with 
generalized chronic periodontitis found in this study 
could potentially constitute a biological marker for 
the progression of different systemic diseases in the 
presence of periodontitis. Also, such phenotype may 
also help to establish variations of this cellular subtype 
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after periodontal therapy to control local infection in 
systemically healthy patients.
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